Zhang Hao, Li Xuan, Wang Xuejian, Xu Wenfang, Zhang Jian
Department of Medical Chemistry, School of Pharmacy, Weifang Medical University.
Department of Cardiology, Weifang Chinese Medicine Hospital.
Drug Discov Ther. 2017;11(3):118-125. doi: 10.5582/ddt.2017.01016.
A series of novel sulfonyl phosphonic 1,4-dithia-7-azaspiro[4,4]nonane derivatives were designed, synthesized, and assayed for their activity against matrix metalloproteinase-2 (MMP-2). Results indicated that all of the compounds exhibited moderate inhibitory activity against MMP-2 compared to LY52 (the control) (IC50 = 0.95 ± 0.09 µM). Several selected compounds were also examined for their antiproliferative activity against SKOV3, HL60, and A549 cells. Notably, all of the tested compounds had slightly lower antiproliferative activity against SKOV3 cells than that of LY52. Compound 6d displayed the greatest inhibitory activity in an enzymatic assay and a cell-based assay, which means that this compound is a good candidate for further development of phosphonate-based MMP inhibitors.
设计、合成了一系列新型磺酰基膦酸1,4-二硫杂-7-氮杂螺[4,4]壬烷衍生物,并检测了它们对基质金属蛋白酶-2(MMP-2)的活性。结果表明,与LY52(对照)相比,所有化合物均表现出对MMP-2的中等抑制活性(IC50 = 0.95±0.09 µM)。还检测了几种选定化合物对SKOV3、HL60和A549细胞的抗增殖活性。值得注意的是,所有测试化合物对SKOV3细胞的抗增殖活性均略低于LY52。化合物6d在酶促试验和基于细胞的试验中表现出最大的抑制活性,这意味着该化合物是进一步开发基于膦酸酯的MMP抑制剂的良好候选物。